Use of Ipilimumab in Metastatic CRPC That Progressed After Docetaxel

Slideset - Ipilimumab after docetaxel failed to significantly prolong overall survival compared with placebo in the intent-to-treat analysis but showed evidence of antitumor activity and stronger benefit in patients with favorable prognostic factors.
Source: Clinical Care Options Prostate Cancer - Category: Cancer & Oncology Source Type: research